Prusiński A, Domzał T, Fryze C, Szczudlik A, Barliński J
Klinik Neurologicznych Akademii Medycznych w Lodzi, Warszawie.
Neurol Neurochir Pol. 1995 Nov-Dec;29(6):835-44.
The authors review data on sumatriptan obtained in the results of their own studies performed on 78 patients in 10 Polish neurological centres. In all 154 migraine attacks were treated with 6 mg of subcutaneous sumatriptan. Significant decrease of pain intensity was achieved in 30% of cases after 15 min and 60%--after 30 min. According to the patient's own opinion, 62% of them evaluated the drug as very efficient, 23% of patients--as efficient. Adverse effects were reported by 11 patients (15%), but they were mild and transient. Headache recurred in 16% of patients.
作者回顾了在波兰10个神经学中心对78例患者进行的自身研究结果中获得的有关舒马曲坦的数据。共对154次偏头痛发作采用6毫克皮下注射舒马曲坦进行治疗。15分钟后30%的病例疼痛强度显著降低，30分钟后60%的病例疼痛强度显著降低。根据患者自身的评价，62%的患者认为该药非常有效，23%的患者认为该药有效。11名患者（15%）报告有不良反应，但均为轻度且短暂性的。16%的患者头痛复发。
